Liver enzyme elevations during statin-ezetimibe therapy in ABCG2 c.421C>A variant carriers: a case series and narrative review.
6 affiliations
- 1Division for Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia.
- 2Department for Chemistry and Biochemistry, University of Zagreb School of Medicine, Zagreb, Croatia.
- 3Department of Basic and Clinical Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia.
- 4University of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia.
- 5Division for Metabolic Diseases, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.
- 6Department of Internal Medicine, University of Zagreb School of Medicine, Zagreb, Croatia.
Abstract
Introduction
Statin-ezetimibe combination therapy is widely used and generally well tolerated; however, liver enzyme elevations may occur during treatment and can be difficult to interpret in patients with polypharmacy and other contributing factors. The potential role of drug-drug-gene interactions (DDGIs) in this context remains insufficiently explored.Materials and methods
We present a series of 11 patients from the PGx-CardioDrug study, selected for documented liver enzyme elevations during statin-ezetimibe therapy that led to treatment modification and carriage of the ABCG2 c.421A allele. Clinical characteristics, treatment history, laboratory findings, and outcomes were reviewed alongside available pharmacogenetic results for genes involved in drug transport and metabolism. Available records of five additional ABCG2 c.421CA carriers with documented normal liver enzyme findings during combination therapy were reviewed for descriptive comparison. A narrative review of the literature was conducted to provide a mechanistic interpretation for the observed findings.Results
The series included six women and five men, aged 27-78 years. Muscle symptoms and/or creatine kinase (CK) elevations were observed in six patients, including two with rhabdomyolysis requiring hospitalization. Dose reduction, drug discontinuation, or switching to alternative lipid-lowering therapy resulted in improvement of laboratory parameters in several patients. In two patients, abnormalities persisted or increased during subsequent ezetimibe monotherapy. Follow-up laboratory results were not available for all patients. Eight patients had the ABCG2 c.421CA genotype and three had c.421AA, consistent with the selection criterion. Additional findings included variants in SLCO1B1, ABCC2, ABCB1, and UGT1A1. In the five potential comparators, normal liver enzyme findings during combination therapy were supported by numerical laboratory values in three patients and clinical documentation in two.Discussion
These cases illustrate the difficulty of interpreting liver enzyme elevations during statin-ezetimibe therapy in patients with concomitant medications and other contributing factors. The narrative review provides a pharmacokinetic rationale for considering DDGIs, but the case series does not establish their contribution to the observed abnormalities. Genotype-based selection, incomplete clinical data, and the small descriptive comparator group limit interpretation. These observations remain hypothesis-generating.
Related
- Effect of rosuvastatin and ezetimibe therapy on LDL-cholesterol reduction and non-invasive arterial injury markers in children with heterozygous familial hypercholesterolemia: a prospective, open-label, randomized study
- Antidepressant Use and Circulating Lipoprotein(a) Levels: A UK Biobank Analysis Including LPA Variant Carriers
- Association between perioperative statin–ezetimibe therapy and reoperation following arthroscopic rotator cuff repair: A TriNetX database study
- Ezetimibe Versus Alirocumab and Plaque Vulnerability in Patients with Acute Coronary Syndrome Not Achieving LDL-Cholesterol Target with Statin Therapy: The COMBI-LLT-ACS Randomized Trial.
- FROM ASYMPTOMATIC CARRIERS TO CADASIL: CONTEXT-DEPENDENT PHENOTYPIC VARIABILITY OF THE NOTCH3 P.ARG1231CYS VARIANT ACROSS THREE EUROPEAN COHORTS AND POTENTIAL IMPLICATIONS OF LDL CHOLESTEROL
BibTeX
@article{simicevic2026liver,
title = {{Liver enzyme elevations during statin-ezetimibe therapy in ABCG2 c.421C>A variant carriers: a case series and narrative review.}},
author = {Livija Šimičević and Lana Ganoci and Ena Karačić and Tamara Božina and Ivan Pećin and Vladimir Trkulja and Nada Božina},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1840055},
url = {https://europepmc.org/article/MED/42898243},
note = {CC BY},
}
RIS
TY - JOUR
TI - Liver enzyme elevations during statin-ezetimibe therapy in ABCG2 c.421C>A variant carriers: a case series and narrative review.
AU - Livija Šimičević
AU - Lana Ganoci
AU - Ena Karačić
AU - Tamara Božina
AU - Ivan Pećin
AU - Vladimir Trkulja
AU - Nada Božina
PY - 2026
DA - 2026/10/05
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1840055
UR - https://europepmc.org/article/MED/42898243
AB - Introduction Statin-ezetimibe combination therapy is widely used and generally well tolerated; however, liver enzyme elevations may occur during treatment and can be difficult to interpret in patients with polypharmacy and other contributing factors. The potential role of drug-drug-gene interactions (DDGIs) in this context remains insufficiently explored.Materials and methods We present a series of 11 patients from the PGx-CardioDrug study, selected for documented liver enzyme elevations during statin-ezetimibe therapy that led to treatment modification and carriage of the ABCG2 c.421A allele. Clinical characteristics, treatment history, laboratory findings, and outcomes were reviewed alongside available pharmacogenetic results for genes involved in drug transport and metabolism. Available records of five additional ABCG2 c.421CA carriers with documented normal liver enzyme findings during combination therapy were reviewed for descriptive comparison. A narrative review of the literature was conducted to provide a mechanistic interpretation for the observed findings.Results The series included six women and five men, aged 27-78 years. Muscle symptoms and/or creatine kinase (CK) elevations were observed in six patients, including two with rhabdomyolysis requiring hospitalization. Dose reduction, drug discontinuation, or switching to alternative lipid-lowering therapy resulted in improvement of laboratory parameters in several patients. In two patients, abnormalities persisted or increased during subsequent ezetimibe monotherapy. Follow-up laboratory results were not available for all patients. Eight patients had the ABCG2 c.421CA genotype and three had c.421AA, consistent with the selection criterion. Additional findings included variants in SLCO1B1, ABCC2, ABCB1, and UGT1A1. In the five potential comparators, normal liver enzyme findings during combination therapy were supported by numerical laboratory values in three patients and clinical documentation in two.Discussion These cases illustrate the difficulty of interpreting liver enzyme elevations during statin-ezetimibe therapy in patients with concomitant medications and other contributing factors. The narrative review provides a pharmacokinetic rationale for considering DDGIs, but the case series does not establish their contribution to the observed abnormalities. Genotype-based selection, incomplete clinical data, and the small descriptive comparator group limit interpretation. These observations remain hypothesis-generating.
SN - 1663-9812
ER -